Unfavorable efficacy to 131I ablation in BRAFV600E mutant papillary thyroid carcinoma with positive TgAb
Metrics: HTML 1227 views | ?
Na Zhang1, Jun Liang2,* and Yan-Song Lin1,*
1Department of Nuclear Medicine, Peking Union Medical College Hospital, Beijing 100730, China
2Department of Oncology, Peking University International Hospital, Beijing 102206, China
*These authors have contributed equally to this work
Jun Liang, email: firstname.lastname@example.org
Yan-Song Lin, email: email@example.com
Keywords: papillary thyroid carcinoma; BRAFV600E mutation; TgAb; radioiodine remnant ablation; efficacy
Received: June 22, 2017 Accepted: August 08, 2017 Published: October 26, 2017
The BRAFV600E mutation has shown a close relationship of aggressiveness in papillary thyroid carcinoma (PTC), while it remains unclear about its influence on the therapeutic response. As a common clinicopathologic risk factor, thyroglobulin antibody (TgAb) may have a correlation of prognosis in PTC. The objective was to investigate the relationship between BRAFV600E mutation and TgAb, and their combined effect on efficacy to radioiodine remnant ablation (RRA). This was a retrospective study including 298 PTC patients and they were divided into four groups according to the combined status. The BRAFV600E mutation rates declined along with increasing TgAb levels in the entire cohort. The ablative efficacy in terms of success or failure rate was statistically different among four groups (89.7%, 74.1%, 67.5%, 57.8%, respectively, P=0.009), group with both positive BRAF and TgAb presented the lowest efficacy. The combined status was associated with the poor efficacy to RRA independently (P=0.029). Among patients with positive TgAb, the effect of RRA in reducing TgAb level might be weakened in BRAF mutant status. The combined status of BRAFV600E mutation and positive TgAb predicts low efficacy to RRA and might be served as an independent unfavorable prognostic factor for PTC. BRAF mutant might weaken the effect of RRA in reducing TgAb levels in PTCs.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.